News Category
Tonix Pharmaceuticals will present its TNX-801 horsepox-based vaccine platform at a major European vaccine conference, highlighting a potential new to...
OrthodontiCell has secured sufficient capital to complete the remaining testing needed to support its application to begin a planned Phase II pivotal ...
hyperCORE International has elected a new executive team to lead its strategic scaling platform, aiming to accelerate growth for independent site netw...
Quantum BioPharma (NASDAQ: QNTM) has received FDA approval to begin Phase 2 testing of Lucid-MS, a first-in-class multiple sclerosis drug that targets...
The American Heart Association's selection of five health technology finalists highlights a push to overcome adoption barriers and accelerate innovati...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola, potentially validating a broad-spectrum antiviral platform tha...
Nutriband Inc. (NASDAQ: NTRB) raised approximately $1.75 million through warrant exercises, funding the remaining clinical development and New Drug Ap...
Leksum LLC has signed an agreement with the Medical University of Vienna to conduct preparatory work for Phase I/II clinical trials of LK-ICU, a thera...
The American Heart Association has expanded its education portfolio with new resources to help clinicians implement the first-ever cardiovascular-kidn...
Newron Pharmaceuticals has received written feedback from the FDA on the clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial, as th...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its neuroprotective Lucid-MS candidate into a Phase 2 trial, poten...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to initiate a Phase 2 trial of Lucid-MS, a novel multiple sclero...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel neuroprotective multiple sclerosis drug Lucid-MS into a ...
XORTX Therapeutics is advancing XORLO, a reformulated gout treatment, toward an FDA new drug application next year, aiming to address tolerability iss...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Lucid-MS Phase 2 trial in multiple sclerosis marks a key step toward clinical ...
NanoViricides will present at the NIBA 153rd Investment Conference, highlighting its broad-spectrum antiviral NV-387, which is in Phase 2 trials for E...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Phase 2 Lucid-MS trial signals progress toward a potential first-in-class mult...
The CDSCO's authorization of Okogen's EMERALD Phase 1/2 study for Treyegen (OKG-0303) marks a significant step toward a much-needed dual-action treatm...
NanoViricides has provided details on its Phase II trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral that could ...
Nutriband's five-year Nasdaq listing anniversary highlights its progress in developing an abuse-deterrent fentanyl patch, a product that could address...
Gianluca Cerri, MD, proposes a personal policy requiring emergency physicians to discuss medication-assisted treatment with opioid use disorder patien...
Stonegate Capital Partners updates coverage on Incannex Healthcare, highlighting the start of patient dosing in the DReAMzz trial and the company's 12...
AAG Zacheriel's debut novel The Vena Protocol: First Blood uses fiction to highlight how commercial pressures can compromise clinical trial data and e...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial for multiple sclerosis, marking a critical step for the company's lead drug candidate, while ...
Quantum BioPharma is advancing its Lucid-MS multiple sclerosis drug to Phase 2 trials while commercializing unbuzzd, a product designed to accelerate ...
A new NFID survey shows high support for vaccines but low uptake due to widespread uncertainty and access barriers, highlighting opportunities for hea...
NanoViricides' fiscal 2026 results reveal progress in its broad-spectrum antiviral NV-387, with Phase II trials approved in the DRC for Mpox and Ebola...
NanoViricides has started dosing patients in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the DRC, marking a key step in devel...
Quantum BioPharma has received FDA approval for its IND application for Lucid-MS, enabling the company to initiate Phase 2 clinical testing of its nov...
Nutriband Inc. appoints former Navy SEAL Robert J. O'Neill to its Advisory Board, bringing elite leadership and advocacy experience as the company adv...
Creative Biolabs introduces a three-part antibody engineering framework to help researchers overcome immunogenicity, efficacy, and developability chal...
FamiCord AG's CDMO division Bramble Bio will establish GMP manufacturing for VERIGRAFT's personalized tissue-engineered vein P-TEV at its Warsaw site,...
The FDA's approval of Quantum BioPharma's IND application for Lucid-MS advances a novel multiple sclerosis treatment into Phase 2 testing, potentially...
Annovis Bio's collaboration with Weave Bio aims to streamline NDA preparation for buntanetap using AI, potentially speeding up regulatory submission f...
Dr. Katherine R. Tuttle will receive the American Heart Association's 2026 Clinical Research Prize for her transformative research on chronic kidney d...
Boston BioLife's 11th anniversary and its co-presentation of the Translational Longevity Summit signal a major push to bridge the gap between longevit...
Tonix Pharmaceuticals secures a second major managed Medicare agreement for its fibromyalgia treatment TONMYA, extending coverage to 32 million Medica...
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid costly clinical trial failures and accelerate development...
A new study reveals that individual microbiome composition influences susceptibility to sepsis, meningitis, and pneumonia from air pollution, highligh...
Peptide Wholesale Supply now applies HPLC testing and batch traceability to bulk orders of BPC-157, Semaglutide, and Tirzepatide, enhancing analytical...
A new push from experts and advocates urges small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging thera...
GeoVax's agreement with CEPI to use its centralized laboratory network for the Phase 3 trial of GEO-MVA could provide independent validation of the va...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer precise delivery pl...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials has treated 43 of 80 patients in its Phase III GelrinC trial, secured a European manufacturing approval that boosts yield by 400...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug, has received FDA clearance for a Phase 2 trial that could revolutionize MS trea...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports natural cartilage regeneration, offering a potential new ...
